Regulatory Status: CE-IVD, AUSTRALIA-IVD, HSA (Singapore)
Colorectal cancer (CRC) is the most common cancer affecting males and 2nd most common after breast cancer for females in Singapore (1). Globally, CRC is the third most common type of cancer making up about 10% of all cases (2). In 2012, it resulted in 1.4 million new cases and caused 694,000 deaths (2). Screening for the mutation status of key genes such as KRAS, NRAS and BRAF can predict patient response to therapies. Professional bodies such as American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) both recommend KRAS mutation testing prior to prescribing EGFR antagonist therapy for patients with metastatic cancer, and also highlight that alternative therapy be used when mutations are detected (3, 4).
This test is intended to aid the oncologist in making therapeutic decisions. Results should be used in conjunction with other available laboratory and clinical information and are not intended for use as a stand-alone diagnostic test or disease monitoring.
10 μm section of FFPE biopsy tissue
Please contact us for more information.
|28 amplicons, 112 mutations|